Annotation Detail
Information
- Associated Genes
- CCNE1
- Associated Variants
-
CCNE1 AMPLIFICATION
(
ENST00000262643.8 )
CCNE1 AMPLIFICATION ( ENST00000262643.8 ) - Associated Disease
- estrogen-receptor positive breast cancer
- Source Database
- CIViC Evidence
- Description
- Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Cell lines with acquired resistance to palbociclib were developed. Two palbociclib-resistant cell lines were derived through chronic exposure to 1 μmol/L palbociclib during 3 to 4 months. Copy number profiling from exome sequencing of MCF-7 and MCF-7pR, confirmed relative amplification of CCNE1. Silencing of CCNE1 or CDK2 alone in MCF-7pR cells had no effect on cell-cycle arrest, but resulted in substantially increased cell-cycle arrest and reduction in cell growth in combination with palbociclib.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1629
- Gene URL
- https://civic.genome.wustl.edu/links/genes/11
- Variant URL
- https://civic.genome.wustl.edu/links/variants/187
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Estrogen-receptor Positive Breast Cancer
- Evidence Direction
- Supports
- Drug
- Palbociclib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 27020857
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Palbociclib | Resitance or Non-Reponse | true |